drugset
drugset / Trial / NCT04826185

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

NCT04826185 ↗

Phase 2 Completed 67 enrolled Imbria Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Timeline

Start
2021-06-14
Primary completion
2023-09-18
Completion
2023-09-18

Outcome

Met primary endpoint

release “The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability” imbria.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ninerafaxstat Small molecule 200 mg Oral

Indications

hypertrophic cardiomyopathy